RYSE is a dedicated team with a strong financial services background combined with medical, research, insurance, and healthcare private equity knowledge.
Managing Partner, RYSE AM – Member of the Investment Committee
Shabir has a long and established track record of building and managing asset management businesses across Europe. He was CEO and Founder of Noble Asset Management Ltd and, prior to this, Co-Founder and Head of Sales and Marketing for PCE Investors Ltd. Previously, Shabir worked within the Prime Brokerage and Equity Finance business of Merrill Lynch and the Equities business at Morgan Stanley.
Managing Partner, RYSE AM – Member of the Investment Committee
From 2009 to 2014, Claudio was the sole Director of Gauss Investments Ltd, an FCA authorised and regulated investment advisor. Previously, he was Head of Sales in EQD to Europe and Middle East at BNP Paribas in London, and a member of the Management Committee. From 2000 to 2005, he worked at Lehman Brothers London in EQF as Head of Sales to Europe.
Head of Investments, RYSE AM – Member of the Investment Committee
Filippo heads the investment analysis at RYSE Asset Management. His main responsibilities include due diligence and portfolio selection, capital raising and bespoke investment vehicle and solution structuring. Between 2015 and 2017 Filippo was in charge of developing the Delta One desk of Louis Capital Markets and previously worked for Hollbeach Investment Management and UniCredit holding roles in London, Munich and Milan.
RYSE AM – Member of the Investment Committee
Roberto was a member of the global healthcare group at private equity investor 3i. He set up Fort Rock Capital, a London-based investor in lifesciences, and then VitaTech, a Luxembourg based platform focused on later stage pan-European healthtech investments. Roberto sits on the boards of GNS Healthcare (USA, digital health and AI), Vasopharm Gmbh (Germany, traumatic brain injury), Medinet (UK, clinical services) and Algenex (Spain, protein production).
He has an MBA from the Wharton School and a degree in economics from Bocconi University.LinkedIn
Dr John Lee Allen
Investment Manager, RYSE AM – Member of the Investment Committee
John is a physician scientist and auditory technology specialist with 15 years of experience across the, public and private, healthcare and life sciences sectors. His interest in digital innovation, and in bringing deep technology to market, developed while building a cochlear implant medical device as a neurosciences PhD student at Oxford University. He has been a repeat founder and investor in healthcare services and consumer health and, as an audiologist, served as a partner for Specsavers Optical Group during their strategic transition into hearing products and services.
Investment Analyst, RYSE AM
Chase assists with investment analysis at RYSE Asset Management. She previously worked as a Business Development Analyst for two years at Ribbon Health, a USA-based predictive analytics and data platform for healthcare enterprises. Her past experience also includes founding her own venture.
Dr Annalisa Jenkins, Senior advisor
Annalisa has approximately 25 years of experience in building and leading teams that advanced programs from scientific research through clinical development, regulatory approval and into healthcare systems globally. Until recently, Annalisa was Chief Executive Officer of Dimension Therapeutics, a gene therapy company focused on developing novel treatments for rare diseases.
Dr. Jenkins has a degree in Medicine from St Bartholomew’s Hospital, served as a Medical Officer in the British Navy and was a Specialist Registrar in Cardiovascular Medicine with UK NHS.
Keith George Gibbs, Senior Advisor
Keith Gibbs retired as Chief Executive of AXA PPP healthcare at the end of 2018, having taken up the role on 17 December 2001. Keith remains non-executive chairman of AXA Global Healthcare and a non-executive director of AXA Venture Partners. Keith served on the council of the International Federation of Health Plans (iFHP) from 2002, spending the final three years (2015 –2018) as chairman.
In 2017, Keith received the UK Health Insurance industry outstanding contribution award. Lately Keith has joined the Advisory Board of HCA International and become a Non-Executive Director of Saga Services Ltd the insurance Broking arm of Saga Plc. Keith is a mathematics graduate and an actuary.
Professor Robert Harris, Senior Advisor
Robert is CEO & Managing Partner of Lakeside Healthcare Group - one of the largest primary care ‘Super-Practices’ in the NHS. He joined LHG in 2014 and since that time, via a series of acquisitions and mergers, has grown the business to its current market-leading position.
He previously worked in a number of senior NHS/UK Government roles: he was the first National Director of Strategy for NHS England/National Commissioning Board; Director of Commissioning & Performance (COO) NHS Midlands & East Strategic Health Authority, with responsibility for over 25% of the NHS; and the first Policy Director at Monitor – the Independent Regulator of NHS Foundation Trusts. He has also served as Senior Healthcare Advisor to a number of overseas governments.
Dr Fiona Adshead, Senior Advisor
Fiona is an independent expert advisor on wellbeing, sustainability, and public health. She is a visiting Professor at UCL, a Senior Associate at Cambridge University’s Sustainability Leadership Programme and Chairs the Sustainable Healthcare Coalition.
Formerly, she was Bupa’s Chief Wellbeing and Public Health Officer, responsible for leading global commercial strategy on workplace health and wellbeing, prevention, behaviour change, partnerships, and sustainability. For five years, she was Deputy Chief Medical Officer and Director General in the UK Government responsible for Health Improvement and Health Inequalities followed by being Director of Chronic Disease and Health Promotion at the World Health Organisation.
Dr Paul Zollinger-Read CBE, Senior Advisor
Paul was formerly Chief Medical Officer at Bupa and had a global role ensuring quality and safety of services internationally. From 2010-12 he was the director of commissioning development at the Midlands and East Strategic Health Authority and from 2011-12 he was a medical advisor and primary care lead at The King's Fund.
Paul became Chief Executive of NHS Cambridgeshire in 2010 and also took on the role of Chief Executive of NHS Peterborough until 2011. In 2009 he took on the post of Chief Executive of Great Yarmouth PCT, continuing his joint GP and leadership role, in 2006 he became Chief Executive of North East Essex PCT and in 2002 he set up the Braintree Care Trust for adult social care, where he was Chief Executive, taking on neighbouring Chelmsford PCT.
Previously, in the mid-1990s he became interested in management and led the Fund Holding Consortium for Braintree. His work focused on waiting lists, national patient access and the Modernisation Agency.
Dr James Kent, Senior Advisor
James was appointed special advisor on health to Theresa May in January 2017. He was formerly a partner and managing director at Boston Consulting Group and before that he trained in medicine in Nottingham and worked as a junior doctor in the NHS.
James has over 30 years of healthcare sector experience as a doctor, consultant and government advisor. He has a incredible track record of designing strategy and policy that has driven change across large complex organisations and systems. He delivered well over a hundred projects across health and life sciences in UK and US. He also built BCG’s NHS practice.
James is a trusted advisor at board and senior ministerial level. brings strategy, organisational and change management skills; clinical and health systems expertise; ability to operate within the private, public and political environments.
James studied Medicine at Nottingham. He is a member of the Royal College of Physicians and gained an MBA from INSEAD.